Staphylococcus aureus–directed liposome for targeted chemotherapy against infection—evaluation of affinity and antibacterial activity
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Antimicrobial Peptides and Activities · Inhalation and Respiratory Drug Delivery · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (24)
Show source-provided references
1. Cilloniz C et al (2023) World pneumonia day 2023: the rising global threat of pneumonia and what we must do about it. Eur Respir J 62(5):230167210.1183/13993003.01672-2023 ↗
2. Wang D et al (2025) Virulence factors in biofilm formation and therapeutic strategies for Staphylococcus aureus: a review. Animals and Zoonoses 1(2):188–20210.1016/j.azn.2024.11.003 ↗
3. Kaushik A et al (2024) Biofilm producing methicillin-resistant Staphylococcus aureus (MRSA) infections in humans: clinical implications and management. Pathogens 13(1):7610.3390/pathogens13010076 ↗
4. Idrees M et al (2021) Staphylococcus aureus biofilm: morphology, genetics, pathogenesis and treatment strategies. Int J Environ Res Public Health 18(14):760210.3390/ijerph18147602 ↗
5. Zhang J et al (2018) Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages. Front Microbiol 9:91510.3389/fmicb.2018.00915 ↗
6. Guo Y et al (2023) Nanotechnology-based drug delivery systems to control bacterial-biofilm-associated lung infections. Pharmaceutics. https://doi.org/10.3390/pharmaceutics1511258210.3390/pharmaceutics15112582 ↗
7. Nikolaizik WH, Trociewicz K, Ratjen F (2002) Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Eur Respir J 20(1):122–12610.1183/09031936.02.00264002 ↗
8. Aronson MR, Medina SH, Mitchell MJ (2021) Peptide functionalized liposomes for receptor targeted cancer therapy. APL Bioeng 5(1):01150110.1063/5.0029860 ↗
9. Gu Z et al (2020) Liposome-based drug delivery systems in cancer immunotherapy. Pharmaceutics. https://doi.org/10.3390/pharmaceutics1211105410.3390/pharmaceutics12111054 ↗
10. Hussain S et al (2018) Antibiotic-loaded nanoparticles targeted to the site of infection enhance antibacterial efficacy. Nat Biomed Eng 2(2):95–10310.1038/s41551-017-0187-5 ↗
11. Jiang J et al (2022) Staphylococcus aureus-targeting peptide/surfactant assemblies for antibacterial therapy. Colloids Surf B Biointerfaces 214:11244410.1016/j.colsurfb.2022.112444 ↗
12. Ye Y et al (2011) Synthesis and evaluation of new iRGD peptide analogs for tumor optical imaging. Bioorg Med Chem Lett 21(4):1146–115010.1016/j.bmcl.2010.12.112 ↗
13. Piraube C et al (1988) Evidence of chemical instability of phospholipids in liposomes. Chem Pharm Bull 36(11):4600–460210.1248/cpb.36.4600 ↗
14. Rinaldi F et al (2021) Rifampicin–liposomes for Mycobacterium abscessus infection treatment: intracellular uptake and antibacterial activity evaluation. Pharmaceutics 13(7):107010.3390/pharmaceutics13071070 ↗
15. Moreira JN et al (2002) Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicity. Pharm Res 19(3):265–26910.1023/A:1014434732752 ↗
16. Ibaraki H et al (2020) The effects of surface properties of liposomes on their activity against Pseudomonas aeruginosa PAO-1 biofilm. J Drug Deliv Sci Technol 57:10175410.1016/j.jddst.2020.101754 ↗
17. Kawano K, Maitani Y (2011) Effects of polyethylene glycol spacer length and ligand density on folate receptor targeting of liposomal doxorubicin in vitro. J Drug Deliv. https://doi.org/10.1155/2011/16096710.1155/2011/160967 ↗
18. Mashreghi M et al (2024) Enhancing the potency of anti-P32-active targeted PEGylated liposomal doxorubicin using various spacers: in silico, in vitro and in vivo studies. J Drug Deliv Sci Technol 101:10623310.1016/j.jddst.2024.106233 ↗
19. Yamamoto S, Sakurai Y, Harashima H (2018) Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption. Int J Pharm 536(1):42–4910.1016/j.ijpharm.2017.11.010 ↗
20. Shmendel E et al (2020) Effects of spacers within a series of novel folate-containing lipoconjugates on the targeted delivery of nucleic acids. J Drug Deliv Sci Technol 57:10160910.1016/j.jddst.2020.101609 ↗
21. Suga T et al (2017) Ligand peptide-grafted PEGylated liposomes using HER2 targeted peptide-lipid derivatives for targeted delivery in breast cancer cells: the effect of serine-glycine repeated peptides as a spacer. Int J Pharm 521(1–2):361–36410.1016/j.ijpharm.2017.02.041 ↗
22. Maruyama K et al (1995) Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochimica et Biophysica Acta (BBA) 1234(1):74–8010.1016/0005-2736(94)00263-O ↗
23. Changsan N et al (2009) Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation. J Pharm Sci 98(2):628–63910.1002/jps.21441 ↗
24. Ma Y et al (2013) Enhanced bactericidal potency of nanoliposomes by modification of the fusion activity between liposomes and bacterium. Int J Nanomedicine 8(1):2351–236010.2147/IJN.S42617 ↗